EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activin A Inhibitory Peptides Suppress Fibrotic Pathways by Targeting Epithelial–Mesenchymal Transition and Fibroblast–Myofibroblast Transformation in Idiopathic Pulmonary Fibrosis

Victor Alexandre F Bastos iD, Patrícia Tiemi Fujimura, Aline Gomes de Souza, Emília Rezende Vaz, Natieli Saito iD, Robinson Sabino-Silva iD, Luiz Ricardo Goulart iD, Thulio Marquez Cunha iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26062705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Victor Alexandre F Bastos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Biotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia 38402-022, MG, Brazil. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Idiopathic Pulmonary Fibrosis, Activins, Myofibroblasts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutos Nacionais de Ciência e Tecnologia, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, National Institutes of Science and Technology in Theranostics and Biotechnology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a progressive and incurable chronic interstitial lung disease characterized by excessive fibrosis and impaired lung function. Current treatments, such as pirfenidone and nintedanib, slow disease progression but fail to halt or reverse fibrosis, highlighting the need for novel approaches. Activin A, which belongs to the TGF-β superfamily, is implicated in various fibrosis-related mechanisms, including epithelial–mesenchymal transition (EMT), a process where epithelial cells acquire mesenchymal characteristics, and fibroblast–myofibroblast transformation (FMT), in which fibroblasts differentiate into contractile myofibroblasts. It also promotes inflammatory cytokine release and extracellular matrix buildup. This study aimed to inhibit Activin A activity using synthetic peptides identified through phage display screening. Of the ten peptides isolated, A7, B9, and E10 demonstrated high binding affinity and inhibitory activity. Computational modeling confirmed that these peptides target the receptor-binding domain of Activin A, with peptide E10 exhibiting superior efficacy. Functional assays showed that E10 reduced cell migration, inhibited EMT in A549 cells, and suppressed FMT in fibroblast cultures, even under pro-fibrotic stimulation with TGF-β. These findings underscore the therapeutic potential of targeting Activin A with synthetic peptides, offering a promising avenue for IPF treatment and expanding the arsenal of anti-fibrotic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionIdiopathic Pulmonary FibrosisActivinsMyofibroblastsFibroblastsPeptidesHumansA549 CellsCell MovementTransforming Growth Factor betaSignal Transduction

Stichwörter der Autor:innen

Activin Aanti-fibrotic therapyepithelial–mesenchymal transitionfibroblast–myofibroblast transformationidiopathic pulmonary fibrosissynthetic peptides

Substanzen

Activinsactivin APeptidesTransforming Growth Factor beta

Autor:innen und Institutionen

  • Laboratory of Experimental Biotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia 38402-022, MG, Brazil.
  • Laboratory of Nanobiotechnology-Prof. Dr. Luiz Ricardo Goulart Filho, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia 38402-022, MG, Brazil.
  • Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirao Preto 14040-900, SP, Brazil.
  • Department of Physiology, Laboratory of Nanobiotechnology-Prof. Dr. Luiz Ricardo Goulart Filho, Innovation Center in Salivary Diagnostics and Nanobiotechnology, Institute of Biomedical Sciences, Federal University of Ub…
  • School of Medicine, Federal University of Uberlândia, Uberlândia 38408-100, MG, Brazil.

ORCID-Profile: Victor Alexandre F Bastos, Natieli Saito, Robinson Sabino-Silva, Luiz Ricardo Goulart, Thulio Marquez Cunha

Förderung

  • Institutos Nacionais de Ciência e Tecnologia
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • National Institutes of Science and Technology in Theranostics and Biotechnology

Zitieren

APA

Bastos, V. A. F., Fujimura, P. T., Souza, A. G., Vaz, E. R., Saito, N., Sabino-Silva, R., Goulart, L. R., & Cunha, T. M. (2025). Activin A Inhibitory Peptides Suppress Fibrotic Pathways by Targeting Epithelial–Mesenchymal Transition and Fibroblast–Myofibroblast Transformation in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062705

Vancouver

Bastos VAF, Fujimura PT, Souza AG, Vaz ER, Saito N, Sabino-Silva R, et al. Activin A Inhibitory Peptides Suppress Fibrotic Pathways by Targeting Epithelial–Mesenchymal Transition and Fibroblast–Myofibroblast Transformation in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062705

BibTeX
@article{Bastos2025,
  author = {Bastos, Victor Alexandre F and Fujimura, Patrícia Tiemi and Souza, Aline Gomes de and Vaz, Emília Rezende and Saito, Natieli and Sabino-Silva, Robinson and Goulart, Luiz Ricardo and Cunha, Thulio Marquez},
  title = {Activin A Inhibitory Peptides Suppress Fibrotic Pathways by Targeting Epithelial–Mesenchymal Transition and Fibroblast–Myofibroblast Transformation in Idiopathic Pulmonary Fibrosis},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26062705}
}
Kostenlos starten →